Efficacy and safety of a combination of metformin and rosiglitaone in patients with type 2 diabetes mellitus--a postmarketing study.
The efficacy and safety of combined metformin and rosiglitazone therapy in type 2 diabetes has been evaluated in an open-label, phase IV, prospective, multicentre study conducted in India over a period of 3 months in accordance with the principles of Good Clinical Practice and the Declaration of Helsinki. The superiority of the combination therapy in its effects on glycaemic parameters and lipid profile has been observed. A discussion of the same with brief review of literature has been presented here.
Ballary
Chetna
C
Medical Services, Glenmark Pharmaceuticals Limited, Mumbai 400026.
Desai
Anish
A
D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008687:Metformin / Q000627:therapeutic use*; D008875:Middle Aged; D011358:Product Surveillance, Postmarketing; D011446:Prospective Studies; D000077154:Rosiglitazone; D013844:Thiazoles / Q000627:therapeutic use*; D045162:Thiazolidinediones; D016896:Treatment Outcome
D007004:Hypoglycemic Agents; D013844:Thiazoles; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D008687:Metformin